Montelukast Ratiopharm

Montelukast, the active ingredient in Montelukast Ratiopharm, is a leukotriene receptor antagonist presented as a tablet for oral use. It treats asthma and allergic rhinitis in adults and children by blocking cysteinyl leukotriene receptors that cause airway inflammation and nasal congestion.

GNH USA supplies Montelukast Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established logistics networks and regulatory expertise to ensure reliable delivery across multiple regions. The company adheres to stringent quality standards and provides comprehensive documentation for import and compliance.

Montelukast is a leukotriene receptor antagonist used to manage conditions driven by cysteinyl leukotriene activity. - Asthma: improves control of persistent asthma and reduces frequency of exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes associated with seasonal or perennial allergic rhinitis. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs after vigorous physical activity.

Montelukast may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea

Serious or Rare Side Effects: - Allergic reactions such as rash, angioedema or anaphylaxis - Neuropsychiatric events including depression, anxiety or suicidal thoughts - Hepatic enzyme elevations or hepatitis - Severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis

When prescribing Montelukast, clinicians should consider several safety precautions. - Assess asthma control before initiating: ensure patient is on appropriate inhaled therapy. - Monitor for neuropsychiatric events: watch for mood changes, depression or suicidal ideation. - Use caution in hepatic impairment: evaluate liver function and adjust if necessary. - Avoid in patients with known hypersensitivity to montelukast or any tablet excipients. - Store at room temperature: keep in the original packaging, protect from moisture and excessive heat.

Montelukast can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Phenobarbital: enzyme induction may lower montelukast plasma concentrations. - Rifampin: strong inducer of CYP enzymes can reduce therapeutic effect. - Ketoconazole: potent CYP3A4 inhibition may increase montelukast levels.

Moderate Interactions (Monitor Closely): - Warfarin: montelukast may potentiate anticoagulant effect, requiring INR monitoring. - Theophylline: concurrent use can increase the risk of theophylline‑related side effects. - Short‑acting β2‑agonists: additive bronchodilation may occur, requiring clinical observation.